Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | RAMP1 | O60894 | 3/20 | 0.30 |
| ▸ | CALCRL | Q16602 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11975732 | 1.00 | ADRB3 (0.43) | ADRB3ADRA2BADRA2CCYP3A4DDB1 | |
| SCHEMBL8237411 | 0.95 | ADRB3 (0.39) | ADRB3ADRA2BADRA2CCYP3A4DDB1 | |
| SCHEMBL11975773 | 0.94 | ADRB3 (0.46) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL13563225 | 0.94 | ADRB3 (0.46) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL17970111 | 0.93 | ADRB3 (0.44) | ADRB3ADRA2BADRA2CCYP3A4DDB1 | |
| SCHEMBL8161544 | 0.93 | ADRB3 (0.44) | ADRB3ADRA2BADRA2CCYP3A4DDB1 | |
| SCHEMBL498005 | 0.93 | ADRB3 (0.44) | ADRB3ADRA2BADRA2CCYP3A4DDB1 | |
| SCHEMBL498004 | 0.93 | ADRB3 (0.44) | ADRB3ADRA2BADRA2CCYP3A4DDB1 | |
| SCHEMBL3970772 | 0.93 | ADRB3 (0.44) | ADRB3ADRA2BADRA2CCYP3A4DDB1 | |
| SCHEMBL13610303 | 0.93 | ADRB3 (0.44) | ADRB3ADRA2BADRA2CCYP3A4DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299021-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2012-10-30 | — | — | US | disclosed |